CRISPR Therapeutics AG · NASDAQ:CRSP

CRISPR Therapeutics — Investor Presentation (January 2024)

32 slides from CRISPR Therapeutics's investor presentation, January 2024

  1. Slide 1: Creating transformative gene-based medicines for serious diseases

    Creating transformative gene-based medicines for serious diseases Corporate Overview | Q4 2023 © 2023 CRISPR Therapeutics 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations about any or all of th

  3. Slide 3: CRISPR Therapeutics Highlights

    CRISPR Therapeutics Highlights Leading gene editing company | Broad pipeline | Best-in-class platform and capabilities Broad pipeline of ex vivo and in vivo programs across four franchises: hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo approaches Historic first approval of

  4. Slide 4: Transforming Medicine Across Four Core Franchises

    Transforming Medicine Across Four Core Franchises Hemoglobinopathies Immuno-oncology First approval of a CRISPR-based Next-generation edited allogeneic gene-editing therapy in the world1 immune cells for cancer Regenerative Medicine In vivo Edited, stem cell-derived beta cells >10 programs using bot

  5. Slide 5: Our Pipeline

    Our Pipeline Program Research IND-enabling Clinical Approved Partner Structure CASGEVY: Severe sickle cell disease (SCD)1 Collaboration Hemoglobin- opathies CASGEVY: Transfusion-dependent β-thalassemia (TDT)1 Next-generation conditioning Wholly owned2 In vivo editing of HSCs CTX112: Anti-CD19 alloge

  6. Slide 6: Potential Functional Cure with CASGEVY (exa-cel)

    Potential Functional Cure with CASGEVY (exa-cel)  CASGEVY (exagamglogene autotemcel [exa-cel]) approved by the U.S. FDA for the treatment of SCD in eligible patients 12 years and older with recurrent vaso-occlusive crises, and granted conditional marketing authorization from the UK MHRA and Bahrain

  7. Slide 7: Exa-cel: Groundbreaking Data Across >95 Patients

    Exa-cel: Groundbreaking Data Across >95 Patients TDT: Transfusion independence achieved out to 45 months SCD: VOC-free and no in-patient hospitalizations for VOCs achieved out to 45.5 months Exa-cel treatment resulted in early and sustained increases in Hb and HbF leading to transfusion independence

  8. Slide 8: Exa-cel has a Large Addressable Market

    Exa-cel has a Large Addressable Market Opportunity to broaden market via innovation in conditioning and delivery β-thalassemia Sickle Cell Disease Exa-cel addressable market with 7,000 standard of care conditioning 25,000 Exa-cel potential market with 16,000 targeted conditioning 150,000 Potential m

  9. Slide 9: Robust Immuno-Oncology Pipeline

    Robust Immuno-Oncology Pipeline  Allogenic platform allows immediate “off-the-shelf” dosing, alleviating the complex supply barriers associated with approved autologous cell therapies  CTX112 and CTX131 advancing in the clinic: Next-generation CAR T candidates with potency edits to improve tumor k

  10. Slide 10: Our Gene-Edited Allogeneic CAR T Franchise

    Our Gene-Edited Allogeneic CAR T Franchise First-generation Next-generation with novel potency edits Further indications/targets Advancing next-gen CTX112 and CTX131 candidates in new areas, e.g., CTX112 in autoimmune Preliminary clinical data suggest disease, GPC3-targeted next-gen may improve upon

  11. Slide 11: CTX112 and CTX131 Incorporate Novel Potency Edits

    CTX112 and CTX131 Incorporate Novel Potency Edits Next-generation CRISPR gene-edited allogeneic CAR T chassis: TGFBR2 CAR disruption TCR MHC I disruption • MHC I KO: Improve disruption • TCR KO: Prevent GvHD persistence in the • Regnase-1 KO: Increase allogeneic setting and functional persistence, a

  12. Slide 12: Regnase-1 and TGFBR2 Knock-Outs Work Synergistically

    Regnase-1 and TGFBR2 Knock-Outs Work Synergistically CAR-T Cell  No TGF-β mediated Tumor microenvironment inhibition Increase in mRNAs that Regnase-1 targets  Increased proliferation  Broad cytokine secretion  Increased cytotoxicity  Repeat response to antigen challenge © 2023 CRISPR Therapeuti

  13. Slide 13: CTX112: Regnase-1/TGFBR2 KO Enhances Potency

    CTX112: Regnase-1/TGFBR2 KO Enhances Potency Potency edits in CTX112 lead to extended survival in Nalm6-Luc mice 100 CTX112: TGFBR2 KO + Regnase-1 KO 80 Regnase-1 KO TGFBR2 KO Survival (%) 60 CTX110 40 Untreated 20 N=15 mice per treated group N=5 mice for untreated group 0 0 20 40 60 80 100 Study da

  14. Slide 14: CTX131 Eliminates Three Successive Tumor Models In Vivo

    CTX131 Eliminates Three Successive Tumor Models In Vivo CTX131 eliminates three different xenograft tumor models in succession without exhaustion Tumor 1: NCI-H1975 (Lung) Tumor 2: Rechallenge 1 with ACHN (RCC) Tumor 3: Rechallenge 2 with Caki-1 (RCC) No treatment CTX131: CTX130 + Regnase-1 KO + TGF

  15. Slide 15: CTX112 and CTX131 Clinical Trials

    CTX112 and CTX131 Clinical Trials Phase 1/2 safety and efficacy Phase 1/2 safety and efficacy study evaluating CTX112 study evaluating CTX131  Relapsed or refractory B-cell malignancies  Relapsed or refractory solid tumors  Expanding into autoimmune diseases with starting with renal cell carcinom

  16. Slide 16: Collaborations with Top Cancer Centers on New Targets

    Collaborations with Top Cancer Centers on New Targets Clinical trial to begin in next 12 months IND-enabling studies to begin this year  First-in-human trial for autologous CAR T  Initial trial for gene-edited, autologous CAR T therapy targeting CD83 therapy targeting GPC3  CD83: Expressed on cer

  17. Slide 17: CRISPR Enables Regenerative Medicine 2.0

    CRISPR Enables Regenerative Medicine 2.0  CRISPR gene editing and pluripotent stem cell technology enable a new class of cell replacement therapies  Developing a beta-cell replacement product that aims to treat diabetes without requiring immunosuppression in partnership with ViaCyte – gene editing

  18. Slide 18: Multi-staged Product Strategy

    Multi-staged Product Strategy Perforated Device Approach Deviceless approach  Progenitor cells (stage 4)  Immature β-cells (stage 6)  Retrievable, enabling broader initial patient population  Portal vein injection 212 211 210  Unencapsulated, stage 6 cell aggregates containing  Entered clinic

  19. Slide 19: VCTX211: Further Optimized for Cell Fitness

    VCTX211: Further Optimized for Cell Fitness VCTX211 has 2 gene KOs and 4 insertions to improve functionality VCTX210 Immune evasion Cell fitness  MHC-I KO eliminates T cell  Thioredoxin interacting protein mediated rejection (TXNIP) KO protects from oxidative and ER stress  PD-L1 KI reduces immun

  20. Slide 20: Edited Cells Evade Immunity In Vitro and In Vivo

    Edited Cells Evade Immunity In Vitro and In Vivo Adaptive – T cells do not respond to 211 cells in vitro Adaptive & Innate – 211 cells survive in humanized mouse model 2.5 T cell proliferation 1.5 2.0 1.5 Luminescence 1.0 1.0 0.5 0.0 Unedited 211 edits T cells alone 0.5 Innate – 211 cells resist NK

  21. Slide 21: VCTX211 Reverses Hyperglycemia in Diabetic Rat Model

    VCTX211 Reverses Hyperglycemia in Diabetic Rat Model Normalization of blood glucose by 12-16 weeks Treated rats maintain glucose sensitivity 600 Insulin Treatment 1500 Blood glucose (mg/dL) 500 Serum C-peptide (pM) 400 Control (no STZ) 1000 STZ 300 200 500 100 STZ Implant 0 0 -5 0 5 10 15 20 25 12 w

  22. Slide 22: In Vivo Platform Advancing Rapidly

    In Vivo Platform Advancing Rapidly  90% of the most prevalent severe monogenic  Developing a multi-modal whole gene correction platform, starting diseases only addressable with gene disruption with AAV+LNP in the liver and advancing to AAV-free, HDR-independent and/or whole gene correction methodo

  23. Slide 23: Becoming an In Vivo Leader – Our Strategy

    Becoming an In Vivo Leader – Our Strategy Focus on disruption and whole gene correction – needed to address ~90% of the most prevalent severe monogenic diseases  Establish a leading platform for in vivo gene disruption, starting in the liver Disruption  Advance a broad portfolio of programs across

  24. Slide 24: Established a Leading mRNA/LNP Platform for Gene Disruption

    Established a Leading mRNA/LNP Platform for Gene Disruption Dose-dependent liver editing up to 70% in NHPs 100 80 Editing in liver (%) 70+% editing in 60 whole liver typically equates to 90+% 40 hepatocyte editing and reduction in 20 serum protein levels 0 0.5 mg/kg 1.5 mg/kg 3 mg/kg Single intraven

  25. Slide 25: Our Initial In Vivo Programs Could Transform the Treatment Paradigm for ASCVD

    Our Initial In Vivo Programs Could Transform the Treatment Paradigm for ASCVD The chronic care model A new treatment paradigm Daily Weekly Multiple infusions Surgical One-time CRISPR-based therapies with medications injections annually interventions the potential to: Recapitulate the proven benefit

  26. Slide 26: CTX310: A One-Time Dose to Stop Expression of ANGPTL3

    CTX310: A One-Time Dose to Stop Expression of ANGPTL3 Intravenous delivery Reduced atherogenic CRISPR/Cas9-based editing of ANGPTL3 targeting the liver lipoprotein concentrations CTX310 Endothelial lipase LDL-C ANGPTL3 Endocytosis and TG Lipoprotein lipase Endosomal escape DNA cleavage and repair Nu

  27. Slide 27: A Single Dose of CTX310 Resulted in Durable Reduction in ANGPTL3 and Triglycerides in NHPs

    A Single Dose of CTX310 Resulted in Durable Reduction in ANGPTL3 and Triglycerides in Non-Human Primates ~70% editing of Sustained reduction in plasma Sustained reduction ANGPTL3 at 1 year ANGPTL3 at 1 year in TG at 1 year 80 0 0 Change from Baseline (%) Change from Baseline (%) -20 -20 60 Liver Edi

  28. Slide 28: Lp(a): An Independent Risk Factor for ASCVD

    Lp(a): An Independent Risk Factor for ASCVD Independent association with long-term MACE8  Lipoprotein(a): an LDL-like lipoprotein synthesized and secreted by hepatocytes that contains apo(a) bound to ApoB  The LPA gene encodes apo(a) and determines plasma Lp(a) levels  Epidemiologic studies, Mend

  29. Slide 29: A Single Dose of CTX320 Resulted in Durable Lp(a) Reduction in NHPs

    A Single Dose of CTX320 Resulted in Durable Lp(a) Reduction in Non-Human Primates ~70% editing of LPA at 1 year ~95% reduction in plasma Lp(a) sustained at 1 year 80 0 Change from Baseline (%) -20 60 Liver Editing (%) -40 40 -60 20 -80 0 -100 1 2 mg/kg 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Study We

  30. Slide 30: Unlocking Whole Gene Correction and Insertion

    Unlocking Whole Gene Correction and Insertion AAV + LNP Next-generation technologies  Proven technologies allow whole gene correction  Dedicated internal group focused on emerging via repair mechanisms at specific loci technologies to allow HDR-independent and/or AAV-free whole gene correction/ins

  31. Slide 31: Strong U.S. and Global Foundational IP Position

    Strong U.S. and Global Foundational IP Position United States Europe and Global CVC granted patents of broad scope; CVC granted foundational patents, multiple applications progressing including use in eukaryotes Patents of broad scope granted in the EU, Canada, China, 55 Patents of broad scope grant

  32. Slide 32: Building a Great Company

    Building a Great Company BEST-IN-CLASS COLLABORATIVE & EXPERIENCED platform and ENTREPRENEURIAL management team capabilities culture INTERNAL ~$1.75 BILLION MANUFACTURING cash balance at state-of-the-art GMP facility CRISPR Therapeutics | www.crisprtx.com As of Q3 2023 © 2023 CRISPR Therapeutics 32

CRISPR Therapeutics — Investor Presentation (January 2024) on 6ix